A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Completed · Phase 2

Conditions studied: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

In brief

To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone

Key facts

Study ID

NCT01447706

Run by

Merrimack Pharmaceuticals

People needed

223

Starts

2011-10-01

Expected to finish

2015-06-01

Last updated by the study team

2016-05-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
• Received at least one prior platinum based chemotherapy regimen
• Platinum-resistant or refractory
• Eligible for weekly paclitaxel
• Adequate liver and kidney function
• 18 years of age or above

You may not qualify if…

• Evidence of any other active malignancy
• History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL

Where it is running

• Arizona Center for Cancer Care — Glendale, Arizona, United States
• Pinnacle Oncology — Scottsdale, Arizona, United States
• Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• Wilshire Oncology Medical Group — Corona, California, United States
• North County Oncology — Oceanside, California, United States
• Central Coast Medical Oncology — Santa Maria, California, United States
• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
• Carolinas Medical Center/Blumenthal Cancer Center — Charlotte, North Carolina, United States
• ProMedica Health System, Inc. — Toledo, Ohio, United States
• Chattanooga GYN Oncology — Chattanooga, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.